参考文献/References:
[1] Funder JW,Carey RM,Mantero F,et al.The management of primary aldosteronism:case detection,diagnosis,and treatment:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.DOI:10.1210/jc.2015-4061.
[2] 虢晶翠,陈小宇,张俊清,等.原发性醛固酮增多症合并肾上腺性库欣综合征的临床特点[J].中华医学杂志,2020,100(36):2828-2833.DOI:10.3760/cma.j.cn112137-20200519-01585.
[3] 刘欣雨,马文君,娄莹,等.31例原发性醛固酮增多症合并亚临床库欣综合征患者回顾分析[J].中国循环杂志,2020,35(10):996-999.DOI:10.3969/j.issn.1000-3614.2020.10.010.
[4] Yasuda S,Hikima Y,Kabeya Y,et al.Clinical characterization of patients with primary aldosteronism plus subclinical Cushing's syndrome[J].BMC Endocr Disord,2020,20(1):9.DOI:10.1186/s12902-020-0490-0.
[5] Hiraishi K,Yoshimoto T,Tsuchiya K,et al.Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome[J].Endocr J,2011,58(7):543-551.DOI:10.1507/endocrj.k10e-402.
[6] Ren K,Wei J,Liu Q,et al.Hypercortisolism and primary aldosteronism caused by bilateral adrenocortical adenomas:a case report[J].BMC Endocr Disord,2019,19(1):63.DOI:10.1186/s12902-019-0395-y.
[7] Zhang Y,Tan J,Yang Q,et al.Primary aldosteronism concurrent with subclinical Cushing's syndrome:a case report and review of the literature[J].J Med Case Rep,2020,14(1):32.DOI:10.1186/s13256-020-2353-8.
[8] Falcetta P,Orsolini F,Benelli E,et al.Clinical features,risk of mass enlargement,and development of endocrine hyperfunction in patients with adrenal incidentalomas:a long-term follow-up study[J].Endocrine,2021,71(1):178-188.DOI:10.1007/s12020-020-02476-1.
[9] Katabami T,Matsuba R,Kobayashi H,et al.Primary aldosteronism with mild autonomous cortisol secretion increases renal complication risk[J].Eur J Endocrinol,2022,186(6):645-655.DOI:10.1530/eje-21-1131.
[10] Tsai CH,Liao CW,Wu XM,et al.Autonomous cortisol secretion is associated with worse arterial stiffness and vascular fibrosis in primary aldosteronism: a cross-sectional study with follow-up data[J].Eur J Endocrinol,2022,187(1):197-208.DOI:10.1530/eje-21-1157.
[11] Akehi Y,Yanase T,Motonaga R,et al.High prevalence of diabetes in patients with primary aldosteronism(PA)associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA:a large,multicenter cohort study in Japan[J].Diabetes Care,2019,42(5):938-945.DOI:10.2337/dc18-1293.
[12] Yanase T,Oki Y,Katabami T,et al.New diagnostic criteria of adrenal subclinical Cushing's syndrome:opinion from the Japan endocrine society[J].Endocr J,2018,65(4):383-393.DOI:10.1507/endocrj.EJ17-0456.
[13] Goupil R,Wolley M,Ungerer J,et al.Use of plasma metanephrine to aid adrenal venous sampling in combined aldosterone and cortisol over-secretion[J].Endocrinol Diabetes Metab Case Rep,2015,2015:150075.DOI:10.1530/EDM-15-0075.
[14] Goh G,Scholl UI,Healy JM,et al.Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors[J].Nat Genet,2014,46(6):613-617.DOI:10.1038/ng.2956.
[15] Cao Y,He M,Gao Z,et al.Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome[J].Science,2014,344(6186):913-917.DOI:10.1126/science.1249480.
[16] Sato Y,Maekawa S,Ishii R,et al.Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome[J].Science,2014,344(6186):917-920.DOI:10.1126/science.1252328.
[17] Beuschlein F,Fassnacht M,Assié G,et al.Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome[J].N Engl J Med,2014,370(11):1019-1028.DOI:10.1056/NEJMoa1310359.
[18] Li X,Wang B,Tang L,et al.Clinical characteristics of PRKACA mutations in Chinese patients with adrenal lesions:a single-centre study[J].Clin Endocrinol(Oxf),2016,85(6):954-961.DOI:10.1111/cen.13134.
[19] Lacroix A,Feelders RA,Stratakis CA,et al.Cushing's syndrome[J].Lancet,2015,386(9996):913-927.DOI:10.1016/s0140-6736(14)61375-1.
[20] Wu WC,Peng KY,Lu JY,et al.Cortisol-producing-adenoma related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion:their prevalence and clinical characteristics[J].Eur J Endocrinol,2022,187(4):519-530.DOI:10.1530/EJE-22-0286.
[21] Fassnacht M,Arlt W,Bancos I,et al.Management of adrenal incidentalomas:european society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors[J].Eur J Endocrinol,2016,175(2):G1-g34.DOI:10.1530/EJE-16-0467.